Study of the effect of Hydroxychloroquine in addition to standard therapy in COVID-19 patients
Not Applicable
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2020/04/024479
- Lead Sponsor
- COMMAND HOSPITAL AIRFORCE
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
a.Patients with oxygen saturation (SPO2) less than 95%
b.Respiratory rate is more than 20/min
c.Pulse rate more than 90/min
d.Imaging evidence of lung infection in the form of Reticulonodular opacities, ground-glass opacities, consolidation and Acute Respiratory Distress Syndrome (ARDS)
Exclusion Criteria
a.Asymptomatic patients
b.Patients with mild illness (not satisfying inclusion criteria)
c.Patients allergic to chloroquine
d.Patients less than 14 years of age
e.Patients unwilling for informed consent
f. Pateints with prolonged QTc interval on ECG
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method number of days of hospitalizationTimepoint: discharge
- Secondary Outcome Measures
Name Time Method death <br/ ><br>days to normalization of SaO2 <br/ ><br>days to normalization of pulse rate less than 90/min <br/ ><br>number of days of requirement of oxygen <br/ ><br>number of days from admission to ventilator requirement <br/ ><br>number of days on ventilator and occurrence of side effectsTimepoint: death or discharge